World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
84
Citations
31583
World Ranking
14939
National Ranking
581

Vittorina Zagonel publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Vittorina Zagonel sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 770 publications — 86th percentile

86% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Vittorina Zagonel D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Vittorina Zagonel sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 84 D-Index — 27th percentile

27% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Vittorina Zagonel is affiliated with the Mario Negri Institute for Pharmacological Research in Italy. Their research predominantly spans the field of Medicine, with a specialized focus on Oncology and related subfields including Pulmonary and Respiratory Medicine, Genetics, Cancer Research, and Surgery.

Their work has extensively addressed topics such as Glioma Diagnosis and Treatment, Cancer Immunotherapy and Biomarkers, Colorectal Cancer Treatments and Studies, Hepatocellular Carcinoma Treatment and Prognosis, Cancer Genomics and Diagnostics, Radiomics and Machine Learning in Medical Imaging, and Renal Cell Carcinoma Treatment.

The following are some of their recent publications:

  • Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial, 2023, The Lancet Oncology
  • Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial, 2020, The Lancet Oncology
  • Recurrent Glioblastoma: From Molecular Landscape to New Treatment Perspectives, 2020, Cancers
  • Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial, 2020, ESMO Open
  • Detection of Molecular Residual Disease Using Personalized Circulating Tumor DNA Assay in Patients With Colorectal Cancer Undergoing Resection of Metastases, 2021, JCO Precision Oncology

Vittorina Zagonel has collaborated frequently with several researchers, including:

  • Giuseppe Lombardi
  • Sara Lonardi
  • Mario Caccese
  • Marta Padovan
  • Francesca Bergamo

Their research appears regularly in prominent venues, with noteworthy publication counts in the following journals:

  • Journal of Clinical Oncology
  • Cancers
  • Annals of Oncology
  • Neuro-Oncology
  • European Journal of Cancer

Best Publications

  • Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.

    Andrew X Zhu;Richard S Finn;Julien Edeline;Stephane Cattan

  • Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma

    Ghassan K. Abou-Alfa;Tim Meyer;Ann Lii Cheng;Anthony B. El-Khoueiry

  • Comprehensive Geriatric Assessment Adds Information to Eastern Cooperative Oncology Group Performance Status in Elderly Cancer Patients: An Italian Group for Geriatric Oncology Study

    Lazzaro Repetto;Lucia Fratino;Riccardo A. Audisio;Antonella Venturino

  • Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer

    Fotios Loupakis;Chiara Cremolini;Gianluca Masi;Sara Lonardi

  • Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): A proof-of-concept, multicentre, open-label, phase 2 trial

    Andrea Sartore-Bianchi;Livio Trusolino;Cosimo Martino;Katia Bencardino

  • ALK+ Lymphoma: Clinico-Pathological Findings and Outcome

    Brunangelo Falini;Stefano Pileri;Pier Luigi Zinzani;Antonino Carbone

  • Prevalence of malnutrition in patients at first medical oncology visit: the PreMiO study

    Maurizio Muscaritoli;Simone Lucia;Alessio Farcomeni;Vito Lorusso

  • Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma

    Vincenzo Mazzaferro;Bassel F El-Rayes;Michele Droz Dit Busset;Christian Cotsoglou

  • Hypermethylation of the DNA repair gene O6-methylguanine DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma

    Manel Esteller;Manel Esteller;Gianluca Gaidano;Steven N. Goodman;Vittorina Zagonel

  • Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial

    Giuseppe Lombardi;Gian Luca De Salvo;Alba Ariela Brandes;Marica Eoli

  • Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study

    Lorenza Rimassa;Eric Assenat;Markus Peck-Radosavljevic;Marc Pracht

  • CHOP is the standard regimen in patients > or = 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group

    U Tirelli;D Errante;M Van Glabbeke;I Teodorovic

  • Assessment of a HER2 scoring system for colorectal cancer: results from a validation study

    Emanuele Valtorta;Cosimo Martino;Andrea Sartore-Bianchi;Frédérique Penaullt-Llorca

  • Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial

    Chiara Cremolini;Carlotta Antoniotti;Daniele Rossini;Sara Lonardi

  • Characterization of Overt B-Cell Lymphomas in Patients With Hepatitis C Virus Infection

    Salvatore De Vita;Cosimo Sacco;Domenico Sansonno;Annunziata Gloghini

  • Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study

    L. Burt Nabors;Karen L. Fink;Tom Mikkelsen;Danica Grujicic

  • Distribution and pattern of BCL-6 mutations throughout the spectrum of B-cell neoplasia

    Daniela Capello;Umberto Vitolo;Laura Pasqualucci;Silvia Quattrone

  • Kaposi's sarcoma-associated herpesvirus DNA sequences in AIDS-related and AIDS-unrelated lymphomatous effusions

    Antonino Carbone;Annunziata Gloghini;Emanuela Vaccher;Vittorina Zagonel

  • Gender medicine: a task for the third millennium.

    Giovannella Baggio;Alberto Corsini;Annarosa Floreani;Sandro Giannini

  • Expression of functional CD40 antigen on Reed-Sternberg cells and Hodgkin's disease cell lines.

    A Carbone;A Gloghini;V Gattei;D Aldinucci

Frequent Co-Authors

Sara Lonardi
Sara Lonardi Istituto Oncologico Veneto
Fotios Loupakis
Fotios Loupakis Istituto Oncologico Veneto
Umberto Tirelli
Umberto Tirelli National Institutes of Health
Matteo Fassan
Matteo Fassan University of Padua
Alfredo Falcone
Alfredo Falcone University of Pisa
Stefano Cascinu
Stefano Cascinu Vita-Salute San Raffaele University
Antonino Carbone
Antonino Carbone Centro di Riferimento Oncologico
Andrea Sartore-Bianchi
Andrea Sartore-Bianchi University of Milan
Salvatore Siena
Salvatore Siena University of Milan
Annunziata Gloghini
Annunziata Gloghini University of Milan

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

The path to a career in medicine is varied and can extend far beyond earning an MD. Many students explore alternative healthcare roles, often accessible through flexible online degree options. Popular choices include becoming a nurse practitioner, registered nurse, or advancing as a nurse educator.

For prospective nurse practitioners seeking affordability and flexibility, exploring the cheapest np school options can make this advanced practice role more accessible. Similarly, those interested in foundational nursing roles often search for what is the cheapest online college for nursing? to start their healthcare journey without overwhelming debt.

Experienced nurses looking to take on research, academic, or leadership positions may consider phd nursing programs online, which can allow them to pursue their goals while maintaining their current roles. Likewise, registered nurses aiming for career advancement or higher salaries can benefit from the cheapest accredited online rn to bsn programs.

Online learning provides flexibility and cost-effective solutions for those dedicated to a healthcare career. Exploring these pathways can help you tailor your medical journey to match your personal and professional goals.

Best Scientists Citing Vittorina Zagonel

Trending Scientists

Recently Published Articles